356 related articles for article (PubMed ID: 30665818)
1. [Interest of a systematic assessment of the treatment of the lower urinary tract symptoms in the management of benign prostatic hypertrophy in general practice (1380 patients) - Study EVALURO].
Descazeaud A; Coloby P; De La Taille A; Kouri G; Mallet R; Rossi D; Rozet F; Zerbib M; Carrois F
Prog Urol; 2019 Feb; 29(2):116-126. PubMed ID: 30665818
[TBL] [Abstract][Full Text] [Related]
2. [Alpha-blockers or phytotherapy as first-line treatment of LUTS/BPH in general medicine: The PERSAT non-interventional study].
de la Taille A; Bardin L; Castagné C; Auges M; Capronnier O; Chalret du Rieu Q
Prog Urol; 2020 Sep; 30(10):522-531. PubMed ID: 32753297
[TBL] [Abstract][Full Text] [Related]
3. The visual prostate symptom score is a simple tool to identify and follow up in general practice patients with lower urinary tract symptoms associated with benign prostatic hyperplasia (a study with 1359 patients).
Descazeaud A; Coloby P; Taille A; Karsenty G; Kouri G; Rossi D; Carrois F; Zerbib M
Presse Med; 2018; 47(7-8 Pt 1):e91-e98. PubMed ID: 30075950
[TBL] [Abstract][Full Text] [Related]
4. Outcomes and general health-related quality of life among patients medically treated in general daily practice for lower urinary tract symptoms due to benign prostatic hyperplasia.
Fourcade RO; Lacoin F; Rouprêt M; Slama A; Le Fur C; Michel E; Sitbon A; Cotté FE
World J Urol; 2012 Jun; 30(3):419-26. PubMed ID: 21892656
[TBL] [Abstract][Full Text] [Related]
5. [Guide dedicated to general practitioner for the management of lower urinary tract symptoms related to benign prostatic hyperplasia].
Descazeaud A; Barry Delongchamps N; Cornu JN; Azzouzi AR; Buchon D; Benchikh A; Coloby P; Dumonceau O; Fourmarier M; Haillot O; Lebdai S; Mathieu R; Misrai V; Saussine C; de La Taille A; Robert G;
Prog Urol; 2015 Jun; 25(7):404-12. PubMed ID: 25841758
[TBL] [Abstract][Full Text] [Related]
6. [Alpha-blockers or hexanic extract of Serenoa repens for 6 months: sub-analysis of the PERSAT study].
de la Taille A; Chalret du Rieu Q; Dialla O; Bardin L
Prog Urol; 2023 Feb; 33(2):66-72. PubMed ID: 36207246
[TBL] [Abstract][Full Text] [Related]
7. Patient-reported outcomes in men with lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH) treated with intraprostatic OnabotulinumtoxinA: 3-month results of a prospective single-armed cohort study.
Sacco E; Bientinesi R; Marangi F; Totaro A; D'Addessi A; Racioppi M; Pinto F; Vittori M; Bassi P
BJU Int; 2012 Dec; 110(11 Pt C):E837-44. PubMed ID: 22712582
[TBL] [Abstract][Full Text] [Related]
8. [Validation of visual prostate symptom score, VPSS, in the evaluation of lower urinary tract symptoms associated with benign prostatic hyperplasia (550 patients)].
Descazeaud A; Coloby P; Davin JL; De La Taille A; Karsenty G; Kouri G; Rossi D; Pouteau JC; Zerbib M
Prog Urol; 2017 Mar; 27(3):176-183. PubMed ID: 28285780
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of a hexanic extract of Serenoa repens (Permixon
Vela-Navarrete R; Alcaraz A; Rodríguez-Antolín A; Miñana López B; Fernández-Gómez JM; Angulo JC; Castro Díaz D; Romero-Otero J; Brenes FJ; Carballido J; Molero García JM; Fernández-Pro Ledesma A; Cózar Olmos JM; Manasanch Dalmau J; Subirana Cachinero I; Herdman M; Ficarra V
BJU Int; 2018 Dec; 122(6):1049-1065. PubMed ID: 29694707
[TBL] [Abstract][Full Text] [Related]
10. A multicenter real-life study of the efficacy of an alpha-blocker with or without anticholinergic agent (imidafenacin) treatment in patients with lower urinary tract symptoms/benign prostatic hyperplasia and storage symptoms.
Cho S; Kwon SS; Lee KW; Yoo TK; Shin DG; Kim SW; Bae JH; Choi H; Kim YH
Int J Clin Pract; 2017 May; 71(5):. PubMed ID: 28508455
[TBL] [Abstract][Full Text] [Related]
11. The efficacy and safety of oral Tamsulosin controlled absorption system (OCAS) for the treatment of lower urinary tract symptoms due to bladder outlet obstruction associated with benign prostatic hyperplasia: an open-label preliminary study.
Lojanapiwat B; Permpongkosol S
Int Braz J Urol; 2011; 37(4):468-76. PubMed ID: 21888698
[TBL] [Abstract][Full Text] [Related]
12. Tadalafil Improves Symptoms, Erectile Function and Quality of Life in Patients with Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia (KYU-PRO Study).
Takahashi R; Miyazato M; Nishii H; Sumino Y; Takayama K; Onzuka M; Oshiro T; Saito S; Fujimoto N; Mimata H; Eto M
Low Urin Tract Symptoms; 2018 Jan; 10(1):76-83. PubMed ID: 29341501
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of Adding Dutasteride to α-Blocker Therapy Treated Benign Prostatic Hyperplasia Patients with Small Volume Prostate (<30 mL).
Hashimoto M; Shimizu N; Sugimoto K; Hongoh S; Minami T; Nozawa M; Yoshimura K; Hirayama A; Tahara H; Uemura H
Low Urin Tract Symptoms; 2017 Sep; 9(3):157-160. PubMed ID: 26991643
[TBL] [Abstract][Full Text] [Related]
14. Construct validation of patient global impression of severity (PGI-S) and improvement (PGI-I) questionnaires in the treatment of men with lower urinary tract symptoms secondary to benign prostatic hyperplasia.
Viktrup L; Hayes RP; Wang P; Shen W
BMC Urol; 2012 Nov; 12():30. PubMed ID: 23134716
[TBL] [Abstract][Full Text] [Related]
15. Influence of baseline variables on changes in International Prostate Symptom Score after combined therapy with dutasteride plus tamsulosin or either monotherapy in patients with benign prostatic hyperplasia and lower urinary tract symptoms: 4-year results of the CombAT study.
Roehrborn CG; Barkin J; Tubaro A; Emberton M; Wilson TH; Brotherton BJ; Castro R
BJU Int; 2014 Apr; 113(4):623-35. PubMed ID: 24127818
[TBL] [Abstract][Full Text] [Related]
16. [The results of the multicenter prospective comparative study of Androgel in men with endogenous testosterone deficiency and lower urinary tract symptoms, associated with benign prostate hyperplasia (POTOK)].
Kogan MI; Avadieva NE; Gevorkyan LS; Loginov YA; Metelkin AM; Mitin AA; Patrikeev AA
Urologiia; 2023 May; (2):32-40. PubMed ID: 37401702
[TBL] [Abstract][Full Text] [Related]
17. [Negative effects on sexual function of medications for the treatment of lower urinary tract symptoms related to benign prostatic hyperplasia].
Descazeaud A; de La Taille A; Giuliano F; Desgrandchamps F; Doridot G
Prog Urol; 2015 Mar; 25(3):115-27. PubMed ID: 25605342
[TBL] [Abstract][Full Text] [Related]
18. Quality of life in patients with lower urinary tract symptoms associated with BPH: change over time in real-life practice according to treatment--the QUALIPROST study.
Alcaraz A; Carballido-Rodríguez J; Unda-Urzaiz M; Medina-López R; Ruiz-Cerdá JL; Rodríguez-Rubio F; García-Rojo D; Brenes-Bermúdez FJ; Cózar-Olmo JM; Baena-González V; Manasanch J
Int Urol Nephrol; 2016 May; 48(5):645-56. PubMed ID: 26810324
[TBL] [Abstract][Full Text] [Related]
19. Alpha-blockers with or without phosphodiesterase type 5 inhibitor for treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia: a systematic review and meta-analysis.
Zhang J; Li X; Yang B; Wu C; Fan Y; Li H
World J Urol; 2019 Jan; 37(1):143-153. PubMed ID: 29948047
[TBL] [Abstract][Full Text] [Related]
20. The association of endothelial nitric oxide synthase (eNOS) G894T gene polymorphism with responsiveness to a selective α1 -blocker in men with benign prostatic hyperplasia related lower urinary tract symptoms.
Lee YC; Juan YS; Liu CC; Bao BY; Wang CJ; Wu WJ; Huang CN; Huang SP
BJU Int; 2016 Aug; 118(2):313-9. PubMed ID: 26940040
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
